Australia markets closed

Bluejay Diagnostics, Inc. (BJDX)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.5470+0.0092 (+1.71%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.47M
Enterprise value -384.96k
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)54.99
Price/book (mrq)0.51
Enterprise value/revenue 5.67
Enterprise value/EBITDA 0.04

Trading information

Stock price history

Beta (5Y monthly) 0.85
52-week change 3-91.69%
S&P500 52-week change 322.38%
52-week high 313.9800
52-week low 30.3900
50-day moving average 30.7177
200-day moving average 32.9693

Share statistics

Avg vol (3-month) 355.14k
Avg vol (10-day) 3134.32k
Shares outstanding 52.69M
Implied shares outstanding 62.69M
Float 81.9M
% held by insiders 116.78%
% held by institutions 17.42%
Shares short (15 Apr 2024) 4370
Short ratio (15 Apr 2024) 40.02
Short % of float (15 Apr 2024) 40.02%
Short % of shares outstanding (15 Apr 2024) 40.01%
Shares short (prior month 15 Mar 2024) 421.95k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 324 July 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-70.09%
Return on equity (ttm)-137.90%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -9.66M
Net income avi to common (ttm)-9.95M
Diluted EPS (ttm)-9.0800
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)2.21M
Total cash per share (mrq)0.82
Total debt (mrq)370.11k
Total debt/equity (mrq)12.78%
Current ratio (mrq)1.82
Book value per share (mrq)2.34

Cash flow statement

Operating cash flow (ttm)-8.31M
Levered free cash flow (ttm)-5.38M